Luke Russell Email

Director, Alliance Management . Vyriad

Current Roles

Employees:
57
Revenue:
$4.4M
About
At Vyriad, we are developing the next generation of targeted cancer therapies using engineered viruses that selectively attack cancer cells and ignite robust immune responses to prevent cancer recurrence. We believe our oncolytic viruses have tremendous potential to improve the lives of patients, inspire hope and change the way cancer is treated. Our goal is to develop effective viral-based therapies for patients, especially those with significant unmet needs. We are testing our oncolytic viruses as monotherapies or in combination with immuno-oncology drugs. Phase 1-2 clinical studies are under way in non-small cell lung cancer, squamous cell carcinoma of the head and neck, metastatic colorectal cancer, bladder and other types of cancer. A Phase 2 trial in several additional forms of cancers is expected to begin enrolling patients by early 2020. Vyriad has clinical research collaboration agreements with Regeneron, Mayo Clinic, Merck KGaA/Pfizer and other leading research and medical institutions
Vyriad Address
2900 37th Street NW
Rochester, MN
United States
Vyriad Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.